U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539155) titled 'Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer' on April 13.
Brief Summary: By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck & Co. (Merck's M-M-R(R) II) into the tumor is safe and effective in making the tumor smaller.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Borderline Resectable/Unresectable Pancreatic Cancer
Non Metastatic Pancreatic Cancer
Intervention:
BIOLOGICAL: Intratumoral MMR Injection
A single dose (0.5 mililiter) of MMR vaccine will be injected under endoscopic ul...